Editorial: Alzheimer drug design based on the amyloid hypothesis

Current Pharmaceutical Design

Volumn 12, Issue 33, 2006, Pages 4281-4282

  Muñoz Torrero, Diego ^a   Camps, Pelayo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; FIBRIN DEPOSITION; HUMAN; IMMUNOTHERAPY; NERVE CELL NECROSIS; NEUROTOXICITY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SENILE PLAQUE; STRUCTURE ANALYSIS;

EID: 33750861596     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778792958     Document Type: Editorial

References (7)

1. DaSilva KA, Aubert I, McLaurin J. Vaccine Development for Alzheimer's Disease. Curr Pharm Design 2006; 12(33): 4283-4293.
2. Nguyen JT, Yamani A, Kiso Y. Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimer's Disease: Progress and Problems. Curr Pharm Design 2006; 12(33): 4295-4312.
3. Ziani-Cherif C, Mostefa-Kara B, Brixi-Gormat FZ. Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research. When, Why and How?. Curr Pharm Design 2006; 12(33): 4313-4335.
4. Leuchtenberger S, Beher D, Weggen S. Selective Modulation of Aβ42 Production: Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Beyond. Curr Pharm Design 2006; 12(33): 4337-4355.
5. Ono K, Naiki H, Yamada M. The Development of Preventives and Therapeutics for Alzheimer's Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as well as Destabilize Preformed fAβ. Curr Pharm Design 2006; 12(33): 4357-4375.
6. Castro A, Martinez A. Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Curr Pharm Design 2006; 12(33): 4377-4387.
7. Pallàs M, Camins A. Molecular and Biochemical Features in Alzheimer's Disease. Curr Pharm Design 2006; 12(33): 4389-4408.